Nektar Therapeutics shares are trading lower after the company announced 52-week data from its Phase 2b REZOLVE-AA study in patients with severe-to-very-severe alopecia areata that may not sufficiently robust for investors. Also, investors may be trimming positions after a 15-month rally with Phase 3 results expected next year.